The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Adenosine hypothesis of schizophrenia – Opportunities for pharmacotherapy
Open accessAbstract
Pharmacotherapy of schizophrenia based on the dopamine hypothesis remains unsatisfactory for the negative and cognitive symptoms of the disease. Enhancing N-methyl-d-aspartate receptors (NMDAR) function is expected to alleviate such persistent symptoms, but successful development of novel clinically effective compounds remains challenging. Adenosine is a homeostatic bioenergetic network modulator that is able to affect complex networks synergistically at different levels (receptor dependent pathways, biochemistry, bioenergetics, and epigenetics). By affecting brain dopamine and glutamate activities it represents a promising candidate for restoring the functional imbalance in these neurotransmitter systems believed to underlie the genesis of schizophrenia symptoms, as well as restoring homeostasis of bioenergetics. Suggestion of an adenosine hypothesis of schizophrenia further posits that adenosinergic dysfunction might contribute to the emergence of multiple neurotransmitter dysfunctionscharacteristic of schizophrenia via diverse mechanisms. Given the importance of adenosine in early brain development and regulation of brain immune response, it also bears direct relevance to the aetiology of schizophrenia. Here, we provide an overview of the rationale and evidence in support of the therapeutic potential of multiple adenosinergic targets, including the high-affinity adenosine receptors (A1R and A2AR), and the regulatory enzyme adenosine kinase (ADK). Key preliminary clinical data and preclinical findings are reviewed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Morris, R. G. M., Anderson, E., Lynch, G. S., & Baudry, M. (1986) · Nature · doi:10.1038/319774a0 · Cited by 3,640
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
A review of MRI findings in schizophrenia
Shenton, M. E., Dickey, C. C., Frumin, M., & McCarley, R. W. (2001) · Schizophrenia Research · doi:10.1016/s0920-9964(01)00163-3 · Cited by 2,346
Synaptic Plasticity: Multiple Forms, Functions, and Mechanisms
Citri, A., & Malenka, R. C. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301559 · Cited by 2,323 · cited 1×
“…has been hypothesised that effective treatment of negative and cognitive symptoms requires boosting of glutamatergic function, especially via N-methyl-Daspartate receptors (NMDARs) that are incidentally critical for some forms of neural plasticity(Citri and Malenka, 2008; Malenka and Nicoll, 1993).”
BackgroundCortical inhibitory neurons and schizophrenia
Lewis, D. A., Hashimoto, T., & Volk, D. W. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1648 · Cited by 2,297
Geyer, M. A., Krebs-Thomson, K., Braff, D. L., & Swerdlow, N. R. (2001) · Psychopharmacology · doi:10.1007/s002130100811 · Cited by 1,484
Adenosine Receptors as Therapeutic Targets
Jacobson, K. A., & Gao, Z.-G. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1983 · Cited by 1,431 · cited 2×
“Central effects of adenosinearemediated via activationof the two high-affinity adenosine receptors A1R and A2AR and the two lowaffinity and low-abundance receptors A2B and A3 (Boison, 2007a,b; Fredholm et al., 2005; Jacobson and Gao, 2006) which are coupled to inhibitory (A1R, A3R) or stimulatory (A2AR, A2BR) metabotr…”
BackgroundAstrocytic Purinergic Signaling Coordinates Synaptic Networks
Pascual, O., Casper, K. B., Kubera, C., Zhang, J., Revilla-Sanchez, R., Sul, J.-Y., Takano, H., Moss, S. J., McCarthy, K., & Haydon, P. G. (2005) · Science · doi:10.1126/science.1116916 · Cited by 1,280 · cited 3×
“The major source for synaptic adenosine is the release of its precursor 5’-adenosinetriphosphate (ATP) from astrocytes, which can occur via vesicular release (Pascual et al., 2005) or via secretion through Boison et al.”
BackgroundIncreased baseline occupancy of D 2 receptors by dopamine in schizophrenia
Abi-Dargham, A., Rodenhiser, J., Printz, D., Zea-Ponce, Y., Gil, R., Kegeles, L. S., Weiss, R., Cooper, T. B., Mann, J. J., Van Heertum, R. L., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.14.8104 · Cited by 1,020
The Neuropsychopharmacology of Fronto-Executive Function: Monoaminergic Modulation
Robbins, T. W., & Arnsten, A. F. T. (2009) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.051508.135535 · Cited by 957
NMDA-receptor-dependent synaptic plasticity: multiple forms and mechanisms
Malenka, R. C., & Nicoll, R. A. (1993) · Trends in Neurosciences · doi:10.1016/0166-2236(93)90197-t · Cited by 904
The tripartite synapse: roles for gliotransmission in health and disease
Halassa, M. M., Fellin, T., & Haydon, P. G. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.12.005 · Cited by 852
Meyer, U., Nyffeler, M., Engler, A., Urwyler, A., Schedlowski, M., Knuesel, I., Yee, B. K., & Feldon, J. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.0099-06.2006 · Cited by 774
Self-citationAdenosine A2A, but not A1, receptors mediate the arousal effect of caffeine
Huang, Z.-L., Qu, W.-M., Eguchi, N., Chen, J.-F., Schwarzschild, M. A., Fredholm, B. B., Urade, Y., & Hayaishi, O. (2005) · Nature Neuroscience · doi:10.1038/nn1491 · Cited by 640
Neurotransmitter roles in synaptic modulation, plasticity and learning in the dorsal striatum
Lovinger, D. M. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.01.008 · Cited by 488 · cited 2×
“048 provides presynaptic inhibition of the release of both glutamate and dopamine, a mechanism that contributes to the complexity of striatal function, which has been extensively reviewed elsewhere (Calabresi et al., 2000a, 2000b; Lovinger, 2010).”
BackgroundRebola, N., Lujan, R., Cunha, R. A., & Mulle, C. (2008) · Neuron · doi:10.1016/j.neuron.2007.11.023 · Cited by 376
Caffeine Induces Dopamine and Glutamate Release in the Shell of the Nucleus Accumbens
Solinas, M., Ferré, S., You, Z.-B., Karcz-Kubicha, M., Popoli, P., & Goldberg, S. R. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-15-06321.2002 · Cited by 338
Alterations of cortical GABA neurons and network oscillations in schizophrenia
Gonzalez-Burgos, G., Hashimoto, T., & Lewis, D. A. (2010) · Current Psychiatry Reports · doi:10.1007/s11920-010-0124-8 · Cited by 260
Meyer, U., Murray, P. J., Urwyler, A., Yee, B. K., Schedlowski, M., & Feldon, J. (2008) · Molecular Psychiatry · doi:10.1038/sj.mp.4002042 · Cited by 252
Self-citationClark, R. S. B., Carcillo, J. A., Kochanek, P. M., Obrist, W. D., Jackson, E. K., Mi, Z., Wisneiwski, S. R., Bell, M. J., & Marion, D. W. (1997) · Neurosurgery · doi:10.1097/00006123-199712000-00010 · Cited by 91
Cited by
Adenosine Kinase: Exploitation for Therapeutic Gain
Boison, D. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.006361 · Cited by 310
Self-citationMatos, M., Shen, H.-Y., Augusto, E., Wang, Y., Wei, C. J., Wang, Y. T., Agostinho, P., Boison, D., Cunha, R. A., & Chen, J.-F. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.02.026 · Cited by 153
Self-citationThe role of P2X7 receptors in a rodent PCP-induced schizophrenia model
Koványi, B., Csölle, C., Calovi, S., Hanuska, A., Kató, E., Köles, L., Bhattacharya, A., Haller, J., & Sperlágh, B. (2016) · Scientific Reports · doi:10.1038/srep36680 · Cited by 52
Cholinergic and Adenosinergic Modulation of Synaptic Release
Yang, D., Ding, C., Qi, G., & Feldmeyer, D. (2021) · Neuroscience · doi:10.1016/j.neuroscience.2020.06.006 · Cited by 24
Sensorimotor gating is disrupted by acute but not chronic systemic exposure to caffeine in mice
Dubroqua, S., Yee, B. K., & Singer, P. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3548-8 · Cited by 10
Self-citation
Metadata
- Authors
- Boison, D., Singer, P., Shen, H.-Y., Feldon, J., & Yee, B. K.
- Venue
- Neuropharmacology
- Publisher
- Elsevier BV
- Published
- 2012-03
- Volume
- 62
- Issue
- 3
- Pages
- 1527-1543
- ISSN
- 0028-3908 (ISSN-L)
- OpenAlex
- W2027478869
- Cited by
- 191
- References
- 20
- FWCI
- 9.22
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.